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Abstract. The Alere Filariasis Test Strip (FTS) is a qualitative, point-of-care diagnostic tool that detects Wuchereria
bancrofti circulating filarial antigen (CFA) in human blood, serum, or plasma. The Global Program to Eliminate Lymphatic
Filariasis employs the FTS for mapping filariasis-endemic areas and assessing the success of elimination efforts. The objec-
tive of this study was to explore the relationship between the intensity of positive test lines obtained by FTS with CFA
levels as determined by enzyme-linked immunosorbent assay (ELISA) with blood and plasma samples from 188 indi-
viduals who live in a filariasis-endemic area. The intensity of the FTS test line was assessed visually to provide a semiquan-
titative score (visual Filariasis Test Strip [vFTS]), and line intensity was measured with a portable spectrodensitometer
(quantitative Filariasis Test Strip [qFTS]). These results were compared with antigen levels measured by ELISA in plasma
from the same subjects. qFTS measurements were highly correlated with vFTS scores (ρ = 0.94; P < 0.001) and with
plasma CFA levels (ρ = 0.91; P < 0.001). Thus, qFTS assessment is a convenient method for quantifying W. bancrofti CFA
levels in human blood, which are correlated with adult worm burdens. This tool may be useful for assessing the impact of
treatment on adult filarial worms in individuals and communities.
INTRODUCTION
Lymphatic filariasis (LF) is a parasitic disease that is a sig-
nificant cause of disability in the developing world. About
90% of the estimated 120 million cases of LF in the world
are caused by the filarial parasite Wuchereria bancrofti.1 The
Global Program to Eliminate Lymphatic Filariasis (GPELF;
coordinated by the World Health Organization [WHO]) aims
to eliminate LF by 2020 using repeated rounds of mass drug
administration (MDA). Diagnostic testing is important for
each phase of this program including mapping, assessing the
impact of MDA, transmission assessment surveys, and post-
MDA surveillance.2–4
At present, three laboratory methods are used for diag-
nosing active infections with W. bancrofti, namely demonstra-
tion of microfilariae (mf) in night blood specimens, detection
of circulating filarial antigens (CFA) released in the blood by
adult worms, and detection of filarial DNA in human blood
by polymerase chain reaction (PCR). Antigen testing is most
widely used at this time, because it is more sensitive and con-
venient for detecting infection than mf testing or PCR.2,5
Two types of antigen tests are currently available: enzyme-
linked immunosorbent assay (ELISA) tests performed in the
laboratory, and point-of-care (POC) rapid tests. ELISA tests
are based on monoclonal antibodies AD12.1 or Og4C3. They
provide quantitative results6,7 but are not practical for routine
use in LF elimination programs. The rapid tests include the
BinaxNOW® Filariasis card test (Alere, Scarborough, ME)
(immunochromatography card test [ICT]), which has been
used in GPELF since 2000, and the Filariasis Test Strip (FTS),
introduced in 2013 by Alere, the successor company to Binax.8
The WHO and the manufacturer recommend qualitative
reading of ICTs and FTS as either positive or negative so
that the result of surveys is generally expressed as preva-
lence of antigenemia. In practice, the test line shows a wide
range of intensity, from clear to dense.
On the basis of the relative intensities of the test (T) and
control (C) lines, ICT scores have been informally used for
many years, assuming a relationship between this score and the
level of CFA and, possibly, with the burden of adult worms.8,9
Although visual scoring of rapid format filarial antigen
tests is useful, more accurate quantitation would represent a
step forward. Rapid quantitation of antigen levels could be
used to assess the effect of treatment on adult worms in indi-
viduals and the impact of MDA on adult worm loads in
communities without the need for ELISA. Therefore, the
purpose of this study was to explore the use of a portable
spectrodensitometer together with the FTS for measuring
CFA levels in human blood to test whether the intensity of
T-lines in positive FTS is correlated with the level of CFA.
MATERIALS AND METHODS
Study area and subjects. This research was performed as
part of a community study in the Democratic Republic of
the Congo (DRC) of the impact of semiannual mass treat-
ment with albendazole on bancroftian filariasis. The trial was
conducted in two villages (Mbumkimi and Misay) that are
situated on the right bank of the Kwilu River in the Bagata
Health Zone (Bandundu Province). Filarial antigen rates
assessed by FTS in June 2014, before any treatment, were
32.5% in Mbumkimi and 31.6% in Misay.
We tested 188 blood samples in this study. These included
110 samples (95 with positive FTS results and 15 negative
samples) collected in July 2014 before any treatment in
the study communities and 78 samples (69 positives and
nine negatives) during a follow-up survey in July 2015 after
two rounds of MDA with albendazole, which has partial
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macrofilaricidal activity against W. bancrofti adult worms.10,11
Because the focus of the study was on quantitation of posi-
tive tests, we oversampled positive tests and selected samples
with range of positivity.
The Ethical Committee for Research in the DRC (Minis-
try of Public Health) approved this study. Written informed
consent was obtained from all adults participating in the
study and from parents or legal guardians of participants
younger than 18 years of age.
The FTS and test performance. Antigen testing was per-
formed with Alere Filariasis Test Strips (Alere, Scarborough,
ME) according to the manufacturer’s instructions. This test
detects a circulating filarial antigen essentially as previously
described for the ICT but with a different platform.2,12 In
brief, 75 μL of finger prick blood is added to a sample appli-
cation pad that contains dried polyclonal antibody to CFA
that has been labeled with colloidal gold. The labeled anti-
body binds to CFA (if it is present), blood cells are retained
in the sample pad, and the labeled antigen–antibody com-
plexes flow down a nitrocellulose strip with the plasma. The
immune complexes are immobilized when they bind to a
monoclonal antibody to CFA that has been striped across
the nitrocellulose membrane, and this results in a positive
test with a visible “T-line.” The procedural control “C-line”
develops when excess labeled polyclonal antibody crosses a
line that contains a secondary antibody to the immunoglobulin
that was in the sample pad. Thus, samples that contain CFA
produce visible T- and C-lines in the FTS, while negative sam-
ples only produce the C-line.
Antigen testing was performed during the day in study vil-
lages. Fingers were cleaned with an alcohol wipe and pricked
with a microtainer contact-activated lancet (Becton Dickenson,
Franklin Lakes, NJ), and 75 μL of blood was collected from
the finger with a plastic micropipette included in the kit and
directly placed onto the FTS sample application pad. A single
trained operator read the FTS at 10 minutes. Visual Filariasis
Test Strip (vFTS) results were scored semiquantitatively as
previously described: negative tests with no visible test (T-)
line were assigned a score of 0, tests with visible T-line weaker
than the control (C-) line were assigned a score of 1, tests with
a T-line that was approximately equal in density to the C-line
were scored 2, and tests with a T-line darker than the C-line
were scored 3.9
Quantitative assessment of filarial antigenemia. Spectrodensi-
tometric measurement of FTS results (quantitative Filariasis
Test Strip). A compact portable spectrodensitometer (FD-5;
Konica-Minolta Inc., Tokyo, Japan) was used to measure the
intensities of the FTS C- and T-lines. The measurements
were performed immediately after the visual reading, that is,
10 minutes after placement of the blood on the sample applica-
tion pad. For reading, completed test strips were placed in a
template produced with unused FTS that were glued onto white
cardboard. The unused strips created a slot that held the used
FTS in place and allowed for consistent spectrodensitometric
reading of the FTS T- and C-lines. Before each measure-
ment, readings were also made using an unused FTS (the
white “target”) for calibration. The target window of the
spectrodensitometer was placed successively on the C- and
T-lines of the used FTS strip. This circular window (diameter:
3.5 mm) was not adapted to the size of the reaction lines.
Hence, the spectrodensitometric readings reflect the entire
field of view of the target window and not just the C- or T-lines.
Background values from the white target were subtracted from
these values to obtainΔRedC-line andΔRedT-line. The quantita-
tive Filariasis Test Strip (qFTS) ratio was defined as ΔRedT-
line:ΔRedC-line. Thus, a qFTS ratio close to 0 should be theoreti-
cally analogous to a vFTS score of 0, a qFTS ratio between
0 and 1 to a vFTS score of 1, a qFTS ratio of approximately 1 to
a vFTS score of 2, and a qFTS ratio > 1 to a vFTS score of 3.
Measurement of circulating filarial antigens by ELISA. Finger
prick blood was collected into heparinized capillary tubes and
stored in a cooler. Tubes were centrifuged, and plasma was
separated and stored at −20°C. The Tropbio Og4C3 ELISA
kit (Cellabs, New South Wales, Australia) was used to
measure CFA levels according to the manufacturer’s instruc-
tions. Samples were tested in duplicate. Kit control standards
(S1–S7) and a conjugate control were also tested in duplicate
on each plate. According to the manufacturer’s instructions,
the standard control sample 1 (S1) should contain less than
10 antigen units (AU); samples with optical density (OD)
values lower than the OD produced by S2 (with 32 AU)
were considered to be negative. Samples with OD values
between those obtained by S2 and S3 (with 128 AU) were
considered to be equivocal. Samples with OD values greater
or equal to the OD obtained with S3 were considered to be
positive for CFA. ELISA assays were performed blindly with-
out reference to the vFTS or qFTS results. The laboratory
testing was performed in the Department of Parasitology at
the National Institute of Biomedical Research in Kinshasa.
Statistical analysis. All reported means are arithmetic
means unless otherwise specified. Differences in mean qFTS
ratios and mean ELISA OD values in the different vFTS
score groups were analyzed using Cuzick’s trend test. We used
Spearman’s rank correlation coefficient to assess the associa-
tions between qFTS, vFTS, and ELISA OD values. Receiver
operating characteristic (ROC) analysis was used to select
cutoff values for ELISA and qFTS data. We first determined
the optimal cutoff for the qFTS ratio using vFTS positivity
as the reference standard. Subsequently, we did the same
using Og4C3 ELISA results as the reference standard. Finally,
kappa scores were calculated to indicate the degree of agree-
ment between different antigen test methods. All statistical
analyses were performed using STATA 14.0 (StataCorp, College
Station, TX), and GraphPad Prism version 6.0e (GraphPad
Software, Inc., La Jolla, CA).
RESULTS
Description of vFTS results. The study was performed with
blood samples from 188 subjects that included 164 (87.2%)
with positive vFTS results. Of study participants, 24 had
a vFTS score of 0 (12.8%), 52 had a score of 1 (27.7%),
38 had a score of 2 (20.2%), and 74 had a score of 3 (39.4%).
Description of qFTS results. Spectrodensitometry data for
C- and T-lines and T:C ratios are shown in Figure 1. A slight
but significant decrease in C-line intensity was observed with
increasing vFTS scores (11.6% decrease in mean C-line inten-
sity for tests with vFTS scores of 3 relatively to the mean for
tests with vFTS scores of 0, P < 0.001 by Cuzick’s trend
test). Mean T-line intensities increased from 0.64 (±0.14)
for vFTS negative individuals to 1.89 (±0.13), 3.51 (±0.28),
and 5.34 (±0.19) for test strips with vFTS scores of 1, 2, and 3,
respectively (P < 0.001 by Cuzick’s trend test). The mean
qFTS ratio was 0.16 (±0.03) for samples that were negative by
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vFTS; qFTS ratios were 0.50 (±0.03), 0.98 (±0.03), and 1.77
(±0.05) for samples with vFTS scores of 1, 2, or 3, respec-
tively (P < 0.001 by Cuzick’s trend test). Although C-line
intensities were slightly decreased in samples with vFTS
scores of 3, we decided that qFTS ratios were better than
T-line densities for presenting qFTS results, since the ratios
tend to correct for variable volumes of plasma due to vari-
able hematocrits between people present in whole blood
samples added to sample application pads. There were highly
significant correlations between qFTS ratios and vFTS scores
when all samples were considered (Spearman’s rank correla-
tion coefficient 0.94; P < 0.001) and when samples collected
before and after MDA were considered separately (ρ = 0.93
and 0.94, respectively; both P < 0.001) (Table 1).
Filarial antigenemia ELISA results. Kit standards pro-
duced valid results on all five plates tested with OD values
< 0.20 for the negative control standard S1 and OD values
> 2.0 for the strong positive control standard S7. Plasma
samples from individuals with vFTS scores of 0, 1, 2, or 3 had
mean OD (± standard deviation) values 0.18 (±0.04), 0.61
(±0.04), 1.32 (±0.05), and 2.12 (±0.05), respectively (P < 0.001
by Cuzick’s trend test) (Figure 2).
Agreement between results of vFTS, qFTS, and ELISA.
Spearman’s rank correlation coefficients between Og4C3
ELISA OD values and vFTS scores were 0.91, 0.92, and
0.90 (all P < 0.001) in the whole, pre-, and post-MDA
populations, respectively (Table 1). Spearman’s rank cor-
relation coefficient for relationship between ELISA OD
and qFTS scores was strong for the whole sample (ρ = 0.91;
P < 0.001) (Figure 3), and in pre- and posttreatment samples
(ρ = 0.90 [P < 0.001] and 0.90 [P < 0.001] respectively)
(Table 1). This suggests that qFTS is as useful as ELISA for
estimating CFA levels and that albendazole treatment does
not influence the correlation.
Sensitivity analysis. Selection of positive cutoff values for
qFTS using vFTS results as a reference standard. An ROC
analysis compared qFTS ratios to qualitative vFTS results
FIGURE 1. Distribution of the densitometer results for the control
line (C-line), the test line (T-line), and the T/C ratios (quantitative
Filariasis Test Strip [qFTS]) according to visual Filariasis Test Strip
(vFTS) results. The optimal cutoff for positivity of qFTS was deter-
mined to be 0.30 (dotted line) using receiver operating characteristic
analysis and vFTS results as reference standard. Solid horizontal lines
represent geometric means and 95% confidence intervals.
TABLE 1
Spearman’s rank correlation coefficients between qFTS ratios, vFTS
scores, and Og4C3 ELISA optical density values
vFTS P values Og4C3 P values
qFTS
Whole population 0.9351 < 0.001 0.9102 < 0.001
Pre-MDA 0.9317 < 0.001 0.9043 < 0.001
Post-MDA 0.9381 < 0.001 0.9020 < 0.001
OD450 Og4C3
Whole population 0.9140 < 0.001 – –
Pre-MDA 0.9156 < 0.001 – –
Post-MDA 0.9047 < 0.001 – –
ELISA = enzyme-linked immunosorbent assay; MDA = mass drug administration; vFTS =
visual Filariasis Test Strip; qFTS = quantitative Filariasis Test Strip.
FIGURE 2. Relationship between the optical density (OD) values
obtained by Og4C3 ELISA and the visual Filariasis Test Strip (vFTS)
scores. Solid horizontal lines represent geometric means and 95%
confidence intervals. ELISA = enzyme-linked immunosorbent assay.
FIGURE 3. Relationship between qFTS ratios and Og4C3 ELISA
OD values for all samples tested by both methods (Spearman’s rank
correlation coefficient ρ = 0.91, P < 0.001) with a fitted regression
line and 95% confidence intervals. ELISA = enzyme-linked immu-
nosorbent assay; OD = optical density; qFTS = quantitative Filariasis
Test Strip.
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(positive [vFTS ≥ 1] or negative [vFTS = 0]) to determine a
cutoff value for positivity using the qFTS ratio (Table 2).
When the qFTS ratio cutoff was 0.30, the sensitivity for
qFTS versus vFTS was 94.9% (95% confidence interval [CI]:
90.6–97.7), specificity was 84% (95% CI: 63.9–95.5), and 93.6%
of the individuals were correctly classified. Using this cutoff,
four individuals had false-positive results (qFTS+/vFTS−) and
nine had false-negative results (qFTS−/vFTS+). All nine
samples of the individuals with qFTS−/vFTS+ had vFTS
scores of 1. Figure 1 illustrates that the placement of the
qFTS ratio cutoff at 0.30 easily discriminated the negative
from the positive vFTS results. The kappa score of 0.73
(P < 0.001) indicates a high level of agreement between vFTS
and qFTS results.13
Selection of a positive cutoff value for qFTS using Og4C3
ELISA results as reference standard. Samples were sorted
into different groups according to their respective OD values.
The negative group contained individuals with an Og4C3
ELISA OD below the OD of the kit standard 2 (32 AU).
A second group contained individuals with Og4C3 results
between OD values obtained with the kit standards 2 and
3 (128 AU) that are equivocal according to the kit guidelines.
A third, positive group contained individuals with ELISA
ODs higher than that obtained with the kit standard 3 (posi-
tive according to the kit guidelines). Subsequently, qFTS ratios
were plotted for all individuals in the different groups, and
qFTS sensitivity and specificity was determined relative to the
ELISA result. This yielded sensitivity and specificity values
for qFTS of 87.2% (95% IC: 81.3–91.8) and 87.5% (95% CI:
61.6–98.5), respectively, when only the negative group was
considered negative, and 93.5% (95% CI: 82.1–98.6) and
89.4% (95% CI: 83.2–94.0), respectively, when samples from
the negative and equivocal group were considered negative.
The corresponding optimal qFTS ratio cutoff values for posi-
tivity were determined by ROC analysis and were placed at
an OD of 0.37 and 0.61, respectively (Figure 4). These qFTS
ratio cutoff values were higher than those obtained when vFTS
results were used as the reference standard.
Comparison of vFTS results with Og4C3 ELISA results.
Table 3 compares vFTS results with Og4C3 ELISA results
using the OD obtained by either kit standard S2 or S3 as
threshold. When kit standard S2 was used as cutoff for
positivity, only 29 of 52 (56%) subjects with vFTS scores
of 1 had positive ELISA results. When kit standard S3 was
used as cutoff for positivity (as recommended by the pack-
age insert) the sensitivity of ELISA for detecting antigen
in samples with vFTS scores of 1 was even lower (10 of 52
or 19%). The S1 negative control in the Og4C3 kit was
negative by vFTS, whereas the S2 in the kit was clearly
positive by vFTS. These results show that vFTS (and indi-
rectly qFTS) is more sensitive than the Og4C3 ELISA for
detecting CFA.
DISCUSSION
WHO guidelines for the GPELF recommend use of filarial
antigen tests for mapping endemic areas and for surveys to
verify that countries have reached elimination targets follow-
ing MDA,14 and the WHO has recently approved the Alere
TABLE 2
The results of a ROC analysis to determine the cutoff for the qFTS
ratios using vFTS results as the reference standard
Sensitivity Specificity
Correctly
classified PPV NPV PLR NLR
qFTS
0.27 96.0 80.0 94.1 97.1 74.1 4.8 0.05
0.30 94.9 84.0 93.6 97.7 70.0 5.9 0.06
0.35 91.0 84.0 90.1 97.6 56.8 5.7 0.11
0.40 90.4 88.0 90.1 98.2 56.4 7.5 0.11
0.43 89.8 92.0 90.1 98.8 56.1 11.2 0.11
NLR = negative likelihood ratio; NPV = negative predictive value; PPV = positive predic-
tive value; PLR = positive likelihood ratio; ROC = receiver operating characteristic; vFTS =
visual Filariasis Test Strip; qFTS = quantitative Filariasis Test Strip ratios.
Sensitivity, specificity, correctly classified, PPV, and NPV results are expressed as percentages.
FIGURE 4. qFTS ratios of individuals that tested negative (OD < S2),
equivocal (S2 < OD < S3), or positive (OD > S3) for circulating filarial
antigen (CFA) by Og4C3 ELISA. The dotted lines represent the
optimal cutoff values determined by receiver operating characteris-
tic analysis when only the negative group was considered negative
(cutoff = 0.37) or when both the negative and equivocal groups
were considered to be negative for CFA (cutoff = 0.61). Solid hori-
zontal lines represent geometric means and 95% confidence inter-
vals. ELISA = enzyme-linked immunosorbent assay; OD = optical
density; qFTS = quantitative Filariasis Test Strip.
TABLE 3
Comparison of vFTS scores and Og4C3 ELISA results using differ-
ent ELISA cutoff criteria
S2 as cutoff S3 as cutoff
Negative Positive Negative Positive
vFTS scores 0 23 1 23 1
1 23 29 42 10
2 0 38 4 34
3 0 76 0 76
vFTS = visual Filariasis Test Strip; ELISA = enzyme-linked immunosorbent assay.
The optical density values are obtained with standards S2 and S3, respectively.
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FTS for this purpose.15 These guidelines assume qualitative
antigen testing (positive or negative), and they do not men-
tion use of these tests for quantifying CFA. We have recently
demonstrated the value of semiquantitative reading of ICTs,9
and this study goes one step further by using spectrodensi-
tometry to measure the relative concentration of CFA in
blood samples. This method allows the user to quantify anti-
gen levels in the field, and it avoids the cost and laboratory
infrastructure required for antigen testing by ELISA. It is
very interesting that qFTS ratios were strongly correlated
with vFTS scores and with OD values obtained with the
Og4C3 ELISA. Since CFA levels are believed to be corre-
lated with adult W. bancrofti worm numbers,16–18 qFTS ratios
should be very useful for assessing the impact of treatment
on adult filarial worms in individuals. Because of its low cost
and simplicity, qFTS holds great promise as a practical, field-
friendly tool for GPELF to measure adult worm burdens at
the community level before and after MDA, much as com-
munity microfilarial load is sometimes used to monitor the
impact of MDA on the community parasite reservoir in LF
and onchocerciasis.19,20 Although qFTS provides a more accu-
rate and objective reading than vFTS, qFTS was slightly less
sensitive than vFTS for reading weak positive antigen tests.
A comparison of qFTS and vFTS results with Og4C3
ELISA results suggests that both the qFTS and vFTS are
more sensitive than the ELISA when the S3 antigen standard
is used as the cutoff for definite positivity as recommended
by the manufacturer. Our results suggest that a significant
proportion of samples that produce OD values in the Og4C3
ELISA between those produced by the S2 and S3 kit stan-
dards are true positives. Low ELISA OD values for some
samples that were positive by vFTS also indicate a lower sen-
sitivity of the ELISA. Hence, filarial infection rates based on
CFA in the blood measured by Og4C3 ELISA will tend to
be underestimated.
Some inconsistencies were detected between results obtained
by qFTS and vFTS; specifically, there was some overlap
between qFTS ratios of samples with vFTS scores of 0 and 1.
Although this could indicate that some vFTS readings were
falsely positive, we think it is more likely that this overlap is
due to imperfect or inconsistent performance of the spectro-
densitometer when T-lines are very light. With the methods
used in this study, vFTS seems better than qFTS for classify-
ing samples as positive or negative when antigen levels are
very low. It should be noted that the spectrodensitometer
used in this study was designed for use in the printing industry
and not optimized for reading FTS. Our homemade template
for positioning FTS strips may have introduced minor reading
errors. However, our study has provided an interesting proof
of principle for quantitative reading of filariasis POC tests. A
purpose-built instrument might produce better results. Such
instruments already exist but they are very expensive. How-
ever, a recent review describes cellphone applications that
have been used to read POC tests for several analytes and
markers of infectious diseases such as malaria and human
immunodeficiency virus,21 and we look forward to further
development of this approach.
We noticed a slight decrease in C-line density (by about
12%) for samples with vFTS scores of 3. This is a minor limi-
tation, because it will tend to increase qFTS ratios for strongly
positive samples. The sample application pad in the FTS con-
tains an excess amount of labeled antibody to CFA, and the
intensity of C-lines was the same for samples with vFTS scores
of 0, 1, or 2. However, samples with high levels of CFA
resulted in strong T-lines (vFTS score of 3) with less labeled
antibody available to produce the C-line. This did not signifi-
cantly affect the main findings of our study. To check on this,
we have recalculated the correlation between qFTS ratios
and Og4C3 levels after increasing C-line intensities by 12%
for samples with FTS scores of 3. The correlation was barely
affected by this adjustment (ρ = 0.90; P < 0.001). To our
knowledge, reduced intensity of C-lines with strongly positive
samples has not previously been described for the FTS or for
other rapid diagnostic tests with a similar design. Researchers
interested in quantitating lateral flow test results should note
this issue.
In conclusion, this study has clearly shown that qFTS ratios
closely correspond to CFA levels as measured by ELISA.
Although further optimization is certainly possible, the spectro-
densitometry method used in this study provides an important
proof of principle. Spectrodensitometric reading of FTS provides
a field-friendly method for rapidly measuring CFA levels that
are related to adult filarial worm counts, which is much more
convenient and less expensive than previously described methods.
Additional work is needed to confirm and extend these prelimi-
nary observations for filariasis and to further explore the use of
spectrodensitometry for measurement of other analytes detected
by POC tests. While POC tests are already widely used in wealthy
countries, they are increasingly being used in resource-limited
settings where physicians and public health workers do not
have ready access to high-quality clinical laboratories.
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